Arvinas News

Buy Rating Affirmed on Arvinas With Promising Trial Updates and Robust Financial Outlook

TipRanks18:24

Arvinas, Inc. (NASDAQ:ARVN) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Arvinas, Inc. (NASDAQ:ARVN) last week reported its latest first-quarter results, which makes it a good time for investors to dive in and see if the business is performing in line with expectations.

Simply Wall St18:05

Analysts Offer Insights on Healthcare Companies: Inogen (INGN), Arvinas Holding Company (ARVN) and UniQure (QURE)

TipRanks10:10

Arvinas Price Target Maintained With a $57.00/Share by Wedbush

Arvinas Price Target Maintained With a $57.00/Share by Wedbush

Dow JonesMay 8 22:27

Wedbush Reiterates Outperform on Arvinas, Maintains $57 Price Target

Wedbush analyst Robert Driscoll reiterates Arvinas (NASDAQ:ARVN) with a Outperform and maintains $57 price target.

BenzingaMay 8 22:16

Arvinas Price Target Cut to $68.00/Share From $72.00 by Stifel

Arvinas Price Target Cut to $68.00/Share From $72.00 by Stifel

Dow JonesMay 8 21:37

Arvinas Is Maintained at Buy by Stifel

Arvinas Is Maintained at Buy by Stifel

Dow JonesMay 8 21:37

Stifel Maintains Buy on Arvinas, Lowers Price Target to $68

Stifel analyst Bradley Canino maintains Arvinas with a Buy and lowers the price target from $72 to $68.

Analyst UpgradesMay 8 21:09

Arvinas Price Target Maintained With a $87.00/Share by HC Wainwright & Co.

Arvinas Price Target Maintained With a $87.00/Share by HC Wainwright & Co.

Dow JonesMay 8 21:03

HC Wainwright & Co. Reiterates Buy on Arvinas, Maintains $87 Price Target

HC Wainwright & Co. analyst Andrew Fein reiterates Arvinas with a Buy and maintains $87 price target.

Analyst UpgradesMay 8 20:53

Arvinas Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 153.42% HC Wainwright & Co. → $87 Reiterates Buy → Buy 04/15/2024 153.42% HC Wainwright & Co. $

BenzingaMay 8 20:51

Oppenheimer Adjusts Arvinas Price Target to $70 From $80, Maintains Outperform Rating

Arvinas (ARVN) has an average rating of Buy and price targets ranging from $38 to $110, according to analysts polled by Capital IQ.

MT NewswiresMay 8 20:36

Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Eledon Pharmaceuticals (ELDN) and Agenus (AGEN)

TipRanksMay 8 20:31

Strong Buy Recommendation for Arvinas Holding Company on Innovative Pipeline and Strategic Partnerships

TipRanksMay 8 19:18

We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth

Yahoo FinanceMay 8 18:57

Arvinas Holding Company (ARVN) Receives a Buy From Barclays

TipRanksMay 8 18:07

Arvinas | 10-Q: Quarterly report

Futu NewsMay 8 04:52 · Announcements

Arvinas Shares Up After Q1 Net Loss Narrows

Arvinas (ARVN) shares were up more than 1% Tuesday after the company reported a Q1 net loss of $0.97 per diluted share, narrowing from a loss of $1.54 a year earlier. Analysts polled by Capital IQ exp

MT NewswiresMay 7 22:27

Arvinas Q1 2024 GAAP EPS $(0.97) Beats $(1.38) Estimate, Sales $25.300M Miss $34.838M Estimate

Arvinas Q1 2024 GAAP EPS $(0.97) Beats $(1.38) Estimate, Sales $25.300M Miss $34.838M Estimate

BenzingaMay 7 19:29

Earnings Flash (ARVN) ARVINAS Reports Q1 Revenue $25.3M

07:23 AM EDT, 05/07/2024 (MT Newswires) -- Earnings Flash (ARVN) ARVINAS Reports Q1 Revenue $25.3M

MT NewswiresMay 7 19:23